Publications
Detailed Information
A Personalized Cancer Nanovaccine that Enhances T-Cell Responses and Efficacy Through Dual Interactions with Dendritic Cells and T Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Go, Seokhyeong | - |
dc.contributor.author | Jung, Mungyo | - |
dc.contributor.author | Lee, Suyoung | - |
dc.contributor.author | Moon, Sangjun | - |
dc.contributor.author | Hong, Jihye | - |
dc.contributor.author | Kim, Cheesue | - |
dc.contributor.author | Chung, Yeonseok | - |
dc.contributor.author | Kim, Byung-Soo | - |
dc.date.accessioned | 2024-06-13T02:10:39Z | - |
dc.date.available | 2024-06-13T02:10:39Z | - |
dc.date.created | 2023-11-20 | - |
dc.date.created | 2023-11-20 | - |
dc.date.issued | 2023-12 | - |
dc.identifier.citation | Advanced Materials, Vol.35 No.49 | - |
dc.identifier.issn | 0935-9648 | - |
dc.identifier.uri | https://hdl.handle.net/10371/204220 | - |
dc.description.abstract | Conventional approaches to developing therapeutic cancer vaccines that primarily activate tumor-specific T cells via dendritic cells (DCs) often demonstrate limited efficacy due to the suboptimal activation of these T cells. To address this limitation, here a therapeutic cancer nanovaccine is developed that enhances T cell responses by interacting with both DCs and T cells. The nanovaccine is based on a cancer cell membrane nanoparticle (CCM-MPLA) that utilizes monophosphoryl lipid A (MPLA) as an adjuvant. To allow direct interaction between the nanovaccine and tumor-specific T cells, anti-CD28 antibodies (aCD28) are conjugated onto CCM-MPLA, resulting in CCM-MPLA-aCD28. This nanovaccine activates tumor-specific CD8+ T cells in both the presence and absence of DCs. Compared with nanovaccines that interact with either DCs (CCM-MPLA) or T cells (CCM-aCD28), CCM-MPLA-aCD28 induces more potent responses of tumor-specific CD8+ T cells and exhibits a higher antitumor efficacy in tumor-bearing mice. No differences in T cell activation efficiency and therapeutic efficacy are observed between CCM-MPLA and CCM-aCD28. This approach may lead to the development of effective personalized therapeutic cancer vaccines prepared from autologous cancer cells. A nanovaccine comprising cancer cell membrane, monophosphoryl lipid A, and anti-CD28 antibodies (named CCM-MPLA-aCD28) activates tumor-specific CD8+ T cells by interacting with both dendritic cells (DCs) and naive T cells. CCM-MPLA-aCD28 exhibits higher efficacy in tumor-specific T cell activation and tumor inhibition than nanovaccines that interact with either DCs (CCM-MPLA) or naive T cells (CCM-aCD28).image | - |
dc.language | 영어 | - |
dc.publisher | WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim | - |
dc.title | A Personalized Cancer Nanovaccine that Enhances T-Cell Responses and Efficacy Through Dual Interactions with Dendritic Cells and T Cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/adma.202303979 | - |
dc.citation.journaltitle | Advanced Materials | - |
dc.identifier.wosid | 001094640500001 | - |
dc.identifier.scopusid | 2-s2.0-85175568959 | - |
dc.citation.number | 49 | - |
dc.citation.volume | 35 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Chung, Yeonseok | - |
dc.contributor.affiliatedAuthor | Kim, Byung-Soo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TUMOR-ANTIGENS | - |
dc.subject.keywordPlus | VACCINES | - |
dc.subject.keywordPlus | DYNAMICS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MAGE-A3 | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordAuthor | cancer vaccines | - |
dc.subject.keywordAuthor | cancer cell membrane | - |
dc.subject.keywordAuthor | dendritic cells | - |
dc.subject.keywordAuthor | T cells | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.